PGNY · Progyny

The thesis

Progyny's record 1.3 million new covered lives and raised 2026 outlook keep the shares modestly more likely than not to beat the S&P 500 over three months, though they now trade above analysts' average target. The first 2027 guidance, expected with the fourth-quarter report around late February 2027, settles whether those lives become revenue.

Progyny administers fertility and family-building benefits for self-insured employers. It is rebuilding growth after losing a large client whose $48.5 million of 2025 revenue is absent from 2026. The 4 November 2026 third-quarter release reported revenue of $341.3 million, up 8.9%, more than 85 new clients and retention near 100% for 2027. The low end of full-year revenue guidance rose to $1.365 billion from $1.360 billion.

The shares closed at $36.58 on 12 November 2026, up 39.2% over three months in adjusted daily closes, and traded to an intraday 52-week high of $37.16 the same session. MarketBeat reported on 9 November 2026 an average analyst target of $35.33, with 11 Buy and four Hold ratings. J.P. Morgan raised its target to $35 from $30 on 9 November 2026 and kept a neutral rating.

The case is wrong on a daily close below the kill line, or if 2026 revenue falls below the low end of guidance.

Bullish and bearish views on Progyny, Inc.

The bull case on Progyny, Inc. (PGNY), in brief: largest selling season on record. The bear case: the beats were narrow.

Bull case

• Largest selling season on record. The company expects more than 660 clients and about 8.3 million covered lives once all new clients are live in 2027, per the 4 November 2026 release. Clients numbered 607 on 30 September 2026, and average members in the third quarter were 7,176,000.
• Reported profit grew faster than revenue. Third-quarter gross margin reached 24.5% against 23.2% a year earlier, and net income rose to $26.3 million from $13.9 million, per the 4 November 2026 release. GAAP (generally accepted accounting principles) diluted earnings per share were $0.32 against $0.15.
• Growth is faster without the departed client. Full-year revenue guidance implies growth of 5.9% to 7.5%, or 10.1% to 11.7% excluding the $48.5 million from the former client, per the company on 4 November 2026. Fourth-quarter revenue guidance is $344.7–$364.7 million.
• Buybacks shrink the share count. The company repurchased nearly 3 million shares for $82.7 million in the third quarter and about 14.3 million since November 2025, per its 4 November 2026 slides. Third-quarter diluted shares were 81.2 million against 90.2 million a year earlier, per Earnings Whispers.
• Analysts raised targets after the report. Citizens moved to $38 from $33, Leerink to $38 from $37, Wells Fargo to $38 from $37 and Cantor Fitzgerald to $35, per MarketBeat on 5 November 2026. J.P. Morgan lifted its target to $35 from $30 on 9 November 2026, per MarketBeat.

Bear case

• The beats were narrow. Revenue of $341.25 million topped consensus by 0.5%, and adjusted EPS of $0.52 beat a $0.51 consensus by one cent, per an Earnings Whispers review on 4 November 2026. The top of full-year revenue guidance stayed at $1.385 billion.
• Buybacks drove per-share growth. Adjusted net income was nearly flat at $42.2 million against $40.8 million, per Earnings Whispers, so the lower share count did most of the work in adjusted EPS. Cash and marketable securities fell to $195.6 million from $236.9 million.
• Adjusted margin slipped. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) rose 6.3% to $58.4 million, slower than revenue, and the margin fell to 17.1% from 17.5%, per the 4 November 2026 release. Management said the investment cycle tapers through 2027.
• Treatment intensity softened. Assisted reproductive technology cycles per female utilizer were 0.50 against 0.52 a year earlier, per Earnings Whispers on 4 November 2026. The fourth-quarter revenue range needs a sequential step-up after roughly flat third-quarter cycles.
• Executives sold into the rally. Chief Executive Peter Anevski sold 236,630 shares at an average $35.84 on 10 November 2026, and 173,247 shares at an average $35.68 across 5 November to 9 November 2026, per SEC Form 4 filings. Executive Chairman David Schlanger sold 35,392 shares at $35.36 on 10 November 2026 and 164,608 shares at an average $35.72 across 5 November to 9 November 2026. All were under Rule 10b5-1 plans, which are pre-scheduled sales, and each followed an option exercise at $0.91.
• The shares sit above the targets. The $36.58 close on 12 November 2026 is above MarketBeat's $35.33 average target of 9 November 2026 and above J.P. Morgan's $35 target.

Price setup

The shares closed at $36.58 on 12 November 2026, after $36.50 on 11 November 2026, $36.43 on 10 November 2026 and $35.95 on 9 November 2026. The 52-week intraday high is $37.16, set on 12 November 2026, and the last close is 1.6% below it. The 52-week closing low is $16.30 on 10 April 2026.

The shares closed at $30.10 on 4 November 2026, the last session before the third-quarter report, and $34.37 on 5 November 2026, a gain of 14.2% in the session, per Finviz. They have held above $34 in every close since. The 50-day average is $28.29 and the 200-day average is $24.76, both as of 12 November 2026, so the shares trade well above both.

No earnings date falls in the next 30 days. Company buying can continue: about $51 million remained under the May 2026 repurchase program as of 4 November 2026.

Catalysts ahead

• ~1 January 2027 (est.): First launches of clients won in the 2027 selling season. Starts converting the 1.3 million new covered lives into members, with most new clients due to go live in the first quarter of 2027.
• ~12 January 2027 (est.): J.P. Morgan Healthcare Conference appearance; date unconfirmed. Progyny has used past appearances there to update financial expectations, so early 2027 commentary may arrive before formal guidance.
• ~25 February 2027 (est.): Fourth-quarter 2026 report and first 2027 guidance; date unconfirmed. Shows whether the record selling season translates into 2027 revenue and whether fourth-quarter revenue reached the $344.7–$364.7 million guidance range.

What would change the view

A daily close below $30, under the $30.10 close on 4 November 2026 before the third-quarter report, which would erase the post-earnings gain. 2026 revenue under the $1.365 billion low end of guidance, or a cut to the 1.3 million new-lives count, would also show the case failing.

The risks this note tracks, each with what would confirm it:

• The record selling season converts into less 2027 revenue than the covered-lives count suggests. Confirmed by: a count under 1.3 million new lives, under about 8.3 million total covered lives, or first 2027 guidance showing little lift from new clients.
• Current-year results fall short of the guidance raised on 4 November 2026. Confirmed by: fourth-quarter 2026 revenue below $344.7 million or full-year revenue below $1.365 billion.
• Softer treatment intensity holds back revenue per member. Confirmed by: assisted reproductive technology cycles per female utilizer staying below the prior-year level at the fourth-quarter report, after 0.50 against 0.52 in the third quarter of 2026.
• Adjusted profitability keeps lagging revenue despite higher gross margin. Confirmed by: an adjusted EBITDA margin below the prior-year quarter at the fourth-quarter report, after 17.1% against 17.5% in the third quarter of 2026.
• Continued insider selling and a price above analyst targets cap further gains. Confirmed by: more Form 4 filings showing executive open-market sales, or analysts holding targets near $35 while the shares trade above them.
• Per-share support weakens as repurchase capacity and cash run down. Confirmed by: the roughly $51 million remaining authorization exhausted with no new program, or cash falling further from $195.6 million.

What it trades with

Progyny's shares move mainly on its own reporting dates and selling-season updates; the 14.2% gain on 5 November 2026 came from company results. Its business depends on employer benefit budgets and fertility treatment utilization. It has little link to drug-development news or to the technology names that drive the broad index.

Two company-specific factors shape how the shares trade: a shrinking share count from repurchases, and seasonal revenue that management ties to summer member activity. Sequential quarters are therefore not directly comparable.